CNSX:LNB

Stock Analysis Report

Lexington Biosciences

Executive Summary

Lexington Biosciences, Inc. develops and commercializes non-invasive diagnostic products for cardiovascular health for home and clinical use.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Lexington Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-12.5%

LNB

-2.5%

CA Medical Equipment

0.3%

CA Market


1 Year Return

-93.0%

LNB

-15.9%

CA Medical Equipment

0.1%

CA Market

Return vs Industry: LNB underperformed the Canadian Medical Equipment industry which returned -15.9% over the past year.

Return vs Market: LNB underperformed the Canadian Market which returned 0.1% over the past year.


Shareholder returns

LNBIndustryMarket
7 Day-12.5%-2.5%0.3%
30 Day133.3%-14.4%-2.5%
90 Day-61.1%-15.4%-1.4%
1 Year-93.0%-93.0%-15.9%-15.9%3.6%0.1%
3 Yearn/a-50.3%-50.3%14.3%4.1%
5 Yearn/a-86.7%-86.7%25.0%6.9%

Price Volatility Vs. Market

How volatile is Lexington Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lexington Biosciences undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Lexington Biosciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Lexington Biosciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of LNB’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Lexington Biosciences regulatory filings.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Lexington Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

56.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lexington Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Lexington Biosciences performed over the past 5 years?

58.9%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: LNB is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare LNB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LNB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (27.4%).


Return on Equity

High ROE: LNB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: LNB is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: LNB is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Lexington Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: LNB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: LNB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: LNB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: LNB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: LNB has a low level of unsold assets or inventory.

Debt Coverage by Assets: LNB has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LNB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: LNB has less than a year of cash runway if free cash flow continues to reduce at historical rates of -19.6% each year


Next Steps

Dividend

What is Lexington Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate LNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LNB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if LNB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LNB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LNB's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Lexington Biosciences's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average board tenure


CEO

Eric Willis (47yo)

2.8yrs

Tenure

CA$263,594

Compensation

Mr. Eric Willis had been the President of Lexington Biosciences, Inc. since May 2017 and serves as its Chief Executive Officer and Secretary since December 21, 2016. Mr. Willis served as the Chief Executiv ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Eric's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Eric's compensation has been consistent with company performance over the past year.


Board Age and Tenure

2.3yrs

Average Tenure

50yo

Average Age

Experienced Board: LNB's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Nick Furber (45yo)

    Chief Financial Officer

    • Tenure: 2.8yrs
    • Compensation: CA$40.66k
  • Eric Willis (47yo)

    CEO, Secretary & Director

    • Tenure: 2.8yrs
    • Compensation: CA$263.59k
  • Donald McInnes

    • Tenure: 0yrs
  • Jonathan Maltz

    Chief Scientific Advisor

    • Tenure: 2.3yrs

Board Members

  • Doug Janzen (50yo)

    Board Chairman

    • Tenure: 0yrs
  • Eric Willis (47yo)

    CEO, Secretary & Director

    • Tenure: 2.8yrs
    • Compensation: CA$263.59k
  • Greg Robertson

    Member of Medical Advisory Board

    • Tenure: 2.3yrs
  • John Disher (61yo)

    Independent Director

    • Tenure: 2.8yrs
  • Jonathan Maltz

    Chief Scientific Advisor

    • Tenure: 2.3yrs
  • James Wall

    Member of Medical Advisory Board

    • Tenure: 2.3yrs
  • Jeffrey Olgin

    Member of Medical Advisory Board

    • Tenure: 2.3yrs

Company Information

Lexington Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lexington Biosciences, Inc.
  • Ticker: LNB
  • Exchange: CNSX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$265.078k
  • Shares outstanding: 3.79m
  • Website: https://www.lexingtonbiosciences.com

Location

  • Lexington Biosciences, Inc.
  • 1055 West Hastings Street
  • Suite 1900
  • Vancouver
  • British Columbia
  • V6E 2E9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
1ZC1DB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2017
LNBCNSX (Canadian National Stock Exchange)YesCommon SharesCACADMay 2017

Biography

Lexington Biosciences, Inc. develops and commercializes non-invasive diagnostic products for cardiovascular health for home and clinical use. It develops HeartSentry, a device for the personalized measurem ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:44
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.